<DOC>
	<DOCNO>NCT01417104</DOCNO>
	<brief_summary>This study do assess effectiveness short term ( ~9 month ) Aliskiren/Placebo therapy slow progression atherosclerotic disease thoracic abdominal aorta . This check compare therapy magnetic resonance imaging ( MRI ) picture aortic wall . Aliskiren FDA approve drug hypertension study use new indication . Recent study animal show Aliskiren therapy reduce atherosclerotic plaque . Therefore , study , investigator would like evaluate whether investigational drug Aliskiren , FDA approve indication beneficial effect people atherosclerotic disease .</brief_summary>
	<brief_title>Aliskiren Effect Aortic Plaque Progression</brief_title>
	<detailed_description>Treatments Clinic Visits : The 36-week double-blind , randomize treatment phase trial precede 2-week single-blind placebo period ass eligibility active treatment period , compliance , confirm baseline blood pressure value enrol subject . If end single-blind phase , inclusion criterion meet , participant allow continue trial . If eligible undergo baseline MRI study randomize either placebo Aliskiren 150 mg , escalation 300 mg 2 week treatment . This dose maintain duration trial . After randomization dose escalation visit ( 2 week ) , patient return schedule clinic visit week 12 36 . Assessment routine safety measure include serum creatinine potassium perform pre-designated visit ( randomization , drug escalation end-of trial ) . At study visit , patient sit position 5 minute , SBP/diastolic blood pressure measure 3 time accordance AHA Committee Report blood pressure determination . The patient ask stand 2 minute , single blood pressure measurement measure stand position . Evidence leave ventricular hypertrophy ( LVH ) determine use Romhilt-Estes scoring system baseline . Specialized measurement plasma include insulin , glucose measure , adipokines ( leptin adiponectin ) high- sensitivity C-reactive protein ( hsCRP ) perform randomization 12 week trial . Central aortic blood pressure assessment perform randomization end trial/exit visit ( SphygmoCor CP , AtCor Medical , Itaska , Illinois , USA ) . Plasma direct renin measurement obtain baseline 12 week part ass compliance patient therapy ( Diasource , Belgium ) .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>Patients , male female , eligible ≥ 45 year age , previously document cardiovascular disease , define least one following : myocardial infarction ( MI ) , cerebrovascular accident ( CVA ) , coronary bypass surgery and/or percutaneous intervention , peripheral arterial disease ( PAD ) , define ankle brachial index ( ABI ) &lt; 0.9 and/or prior peripheral intervention/surgery . Subjects angiotensinconverting enzyme inhibitor ( ACEI ) angiotensin receptor blocker ( ARB ) therapy eligible participate , provide dose adjustment make course study . Contraindications MRI exam ( pacemaker , metallic implant , severe claustrophobia ) ; diagnosis Type II Diabetes use hypoglycemic drug ; uncontrolled hypertension ( &gt; 145/90 mm Hg ) ; low density lipoprotein ( LDL ) ≥ 130mg/dL ; renal insufficiency define glomerular filtration rate ( GFR ) ≤ 40 ml/minute ( derive Modified Diet Renal Disease ( MDRD ) equation ) ; initiation new therapy statin , ACEI/ARBs , antioxidant , calcium channel blocker , diuretic , β blocker ; transient ischemic cerebral attack prior 6 month ; history allergy renin inhibitor ; unstable cardiac syndrome ; symptomatic arrhythmia ; history malignancy include leukemia lymphoma ( basal cell skin cancer , cure squamous cell cancer localize prostate cancer ) history allergy renin inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>plaque</keyword>
	<keyword>magnetic resonance imaging ( MRI )</keyword>
	<keyword>high blood pressure</keyword>
	<keyword>MI</keyword>
	<keyword>heart attack</keyword>
	<keyword>CVA</keyword>
	<keyword>stroke</keyword>
	<keyword>PAD</keyword>
</DOC>